

Life Quality Assessment in Patients with Type 1 Spinocerebellar Ataxia in the Yakut Population

A.A. Maksimova^{1,*}, A.I. Fedorov¹, A.L Sukhomyasova^{1,2} and N.R. Maksimova¹

¹ M.K. Ammosov North-Eastern Federal University, Yakutsk, Russia

² State Autonomous Institution of the Republic of Sakha (Yakutia) Republic Hospital No. 1 National Center of Medicine, Yakutsk, Russia

*Corresponding author. Email: aa.maksimova@s-vfu.ru

ABSTRACT

Parameters of life quality in 12 patients with type 1 spinocerebellar ataxia (SCA1) in the Yakut population were studied. The control group was 12 healthy individuals. A SF-36 questionnaire was used to determine life quality, reflecting overall well-being and satisfaction degree with the physical and psychological components of health. According to the research results, a decrease in the life quality occurs for most indicators of hereditary neurological pathology. This is evidenced by statistically significant differences in their averages compared to healthy individuals. A life quality feature of Yakut SCA1 patients can be considered a relatively good preservation of mental health. Patients also maintain vital activity, normal level of communication and social contacts that are quite comparable to those of healthy persons.

Keywords: life quality, type 1 spinocerebellar ataxia, SCA1, Yakutia

1. INTRODUCTION

Spinocerebellar ataxias (SCAs) are one of the inherited progressive neurodegenerative disorders and belong to the phenotypically and genetically diverse group of cerebellar ataxias. Many of the SCAs have an autosomal dominant inheritance pattern. The prevalence of SCAs is known as 1–5 cases per 100,000 persons [1].

Each SCA have different clinical manifestations, and mutations in more than 30 distinct genetic loci encoding protein kinases, protein phosphatases, membrane receptors, intracellular ion channels, plasma membrane, and protein with unknown function [2].

Approximately 80 % of autosomal dominant SCA cases are one of SCA 1, 2, 3, 6, and 7, which are the most common polyQ expansion disorders [3, 4].

Spinocerebellar ataxia type 1 (SCA1) (OMIM 164400) refers to polyglutamine diseases characterized by a dynamic mutation – expansion of trinucleotide repeats of cytosine-adenine-guanine (CAG) in the coding regions of the corresponding genes [5, 6]. Clinical manifestations of type 1 spinocerebellar ataxia

(SCA1) are characterized by the development of cerebellar-pyramid syndrome, its rapid progression, leading to social dysadaptation of patients, to a significant decrease in their life expectancy [7].

Typical SCA1 presents during the third or fourth decades (ranging from 7 to 50 years) with symmetric gait abnormality and progressive ataxia related to cerebellar dysfunction. Many patients are wheelchairbound by the age of 15–20 years. Pathologic findings are associated with atrophy in Purkinje cells of not only the cerebellum but also the pons and middle cerebellar peduncle. SCA1 is characterized by extracerebellar features and corticospinal tract dysfunctions such as hyperreflexia and spasticity in more than 50 % of patients [8, 9].

Life quality is one of the main indicators of wellbeing for patients with SCA1 that cannot be cured.

Life quality (LQ) (by WHO definition) is a characteristic of physical, psychological, emotional and social functioning, based on its subjective perception.

The life quality study is becoming an urgent and integral problem in the management of patients with various diseases. LQ is an assessment of the effect of the disease and treatment on its physical, psychological, emotional and social functioning. It is associated with the clinical endpoints, which makes this indicator very important in clinical studies [10]. The SF-36 questionnaire (Medical Outcomes Study Short-Form 36) is the most common standardized tool for studying LQ in a population, allowing to evaluate different components of patient's life.

Due to extensive use and experience across patients and general population, the generic SF-36 questionnaire also allows to compare patient perceived health status across a variety of disorders and with the general population [11].

The aim of the present research was to assess the life quality of patients with SCA type 1 in the Yakut population.

2. MATERIALS AND METHODS

The study included 12 patients diagnosed with SCA1 who were admitted to the Medical and Genetic Center (MGC) of the "Republic Hospital No. 1 – National Center of Medicine" between March and May 2021. The control group was 12 healthy people. The assessment of the life quality of patients with SCA1 and a healthy population was carried out with non-specific questionnaire SF-36 (SF-36 Health Status Survey), adapted by the Institute of Clinical and Pharmacological Research, St. Petersburg.

The results of the survey were standardized for the US general population. Primary data processing was carried out according to instructions developed by Evidence Clinical and Pharmacological Research.

The questionnaire contains 36 questions aimed at identifying the life quality of respondents according to 8 scales: physical functioning, role-playing activities, body pain, general health, vitality, social functioning, emotional state and mental health (Tab. 1). A score of results is used, where large values correspond to a high level of life quality. In turn, scales form physical and psychological components of health (Fig. 1).

Table 1. Content of the SF-36 Health Survey.

Label SF-36 QUESTIONS
GH1 1. In general, would you say your health is:
HT 2. Compared to one year ago, how would you rate
your health in general now?
3. The following items are about activities you might do
during a typical day. Does your health now limit you in
these activities? Is so, how much?
PF01 a. Vigorous activities, such as running, lifting
heavy objects, participating in strenuous sports
PF02 b. Moderate activities, such as moving a table,
pushing a vacuum cleaner, bowling, or playing golf
PF03 c. Lifting or carrying groceries

PF04 d. Climbing several flights of stairs **PF05** e. Climbing one flight of stairs **PF06** f. Bending, kneeling, or stooping g. Walking more than a mile **PF07 PF08** h. Walking several blocks **PF09** i. Walking one block **PF10** j. Bathing or dressing yourself 4. During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of your physical health? a. Cut down on the amount of time you spent RP1 on work or other activities RP2 b. Accomplished less than you would like RP3 c. Were limited in the kind of work or other activities RP4 d. Had difficulty performing the work or other activities (for example, it took extra effort) 5. During the past 4 weeks, have you had any of the following problems with your work or other regular daily activities as a result of any emotional problems (such as feeling depressed or anxious) RE1 a. Cut down on the amount of time you spent on work or other activities RE2 b. Accomplished less than you would like RE3 c. Didn't do work or other activities as carefully as usual SF1 6. During the past 4 weeks, to what extent has your physical health or emotional problems interfered with your normal social activities with family, trends, neighbors, or groups? BP1 7. How much bodily pain have you had during the past 4 weeks? BP2 8. During the past 4 weeks, how much did pain interfere with your normal work (including both work outside the home and housework)? 9. These questions are about how you feel and how things have been with you during the past 4 weeks. For each question, please give the one answer that comes closest to the way you have been feeling. How much of the time during the past 4 weeks a. Did you fed full of pep? VT1 MH1 **b.** Have you been a very nervous per son? MH2 c. Have you felt so down in the dumps that nothing could cheer you up? d. Have you felt calm and peaceful? MH3 VT2 e. Did you have a lot of energy? MH4 f. Have you felt downhearted and blue? VT3 g. Did you fed worn out? MH5 h. Have you been a happy person? VT4 i. Did you feel tired? SF2 10. During the past 4 weeks, how much of the time has your physical health or emotional problems interfered with your social activities (like visiting with friends, relatives, etc.)? 11. How TRUE or FALSE is each of the following statements for you? a. I seem to get sick a little easier than other GH2 people GH3 b. I am as healthy as anybody I know GH4 c. I expect my health to get worse GH5 d. My health is excellent **RESPONSE CHOICES** SF-36 Excellent, Very good. Good, Fair, Poor Much better now than one year ago, Somewhat better now than one year ago. About the same as one year ago, Somewhat worse now than one year ago, Much worse now than one year ago Yes, limited a lot; Yes. limited a little; No, not limited at all

& 5. Yes, No
Not at all, Slightly, Moderately, Quite a bit, Extremely
None. Very mild. Mild, Moderate, Severe, Very severe
Not at all, A little bit. Moderately, Quite a bit, Extremely
All of the time. Most of the time, A good bit of the time.
Some of the time, A little of the time, None of the item
All of the time. Most of the time. Some of the time, A
little of the time, None of the time
Definitely true. Mostly true. Don't know. Mostly false.
Definitely false

The study materials were statistically processed with parametric and non-parametric analysis methods. The accumulation, adjustment, systematization of initial information was carried out by Microsoft Office Excel 2016. Statistical analyses were performed by IBM SPSS Statistics v.23. Arithmetic mean values, standard deviations and coefficient of variation were calculated. The Mann-Whitney U-test was used to compare mean values in study groups.



Figure 2. The structure of the Short Form 36 Health Survey (SF-36) instrument

3. RESULTS AND DISCUSSION

The study sample shows broad variability in the life quality of the surveyed population (Table 1).

Table 1. Generalized indicators of the life quality of patients with SCA1 and healthy representatives of the Yakut population

life quality parameters	n	М	σ	U
Physical functioning	24	70.8	29.1	41.1
Role function due to physical condition	24	57.2	42.6	74.4

Pain intensity	24	62.4	28.2	45.2
General health	24	52.5	20.3	38.6
Life activity	24	51.2	21.4	41.8
Social functioning	24	64.0	27.4	42.7
Emotional Role Function	24	50.0	41.7	83.4
Mental health	24	62.0	17.0	27.4
Physical component of health	24	60.7	25.2	41.5
Psychological component of health	24	56.8	23.2	40.9
Average Life Quality Assessment	24	58.7	23.0	39.1

Note: n-number of observations; M- average value; $\sigma-$ standard deviation; $\upsilon-$ variation coefficient

The coefficient of variation, expressed in percentage, exceeds 30 % threshold for all scales and components of the questionnaire, which indicates the heterogeneity of the indicators. The maximum level of variability is noted according to the scales "Role functioning due to emotional state" and "Role functioning due to physical state."

The life quality of SCA1patients is characterized by a significant decrease in indicators by the scales "Role functioning due to emotional state" and "Role functioning due to physical state," where the lowest average level of scores and their strong variation exceeding 100 % (Table 2).

Table 2. Indicators of life quality of SCA1 patients

Life quality parameters	n	М	σ	U
Physical functioning	12	51.2	27.4	53.6
Role function due to physical condition	12	33.3	35.8	107.6
Pain intensity	12	48.5	26.1	53.8
General health	12	45.0	22.2	49.3
Life activity	12	50.4	16.3	32.3
Social functioning	12	58.3	24.6	42.2
Emotional Role Function	12	25.0	35.1	140.7
Mental health	12	60.6	15.5	25.5
Physical component of health	12	44.5	22.6	50.8
Psychological component of health	12	48.6	19.8	40.8
Average Life Quality Assessment	12	46.5	20.6	44.4

Note: n- number of observations; M- average value; $\sigma-$ standard deviation; $\upsilon-$ variation coefficient

Among healthy representatives of the Yakut population, relatively high quality levels were observed for all scales and components of the questionnaire (Table 3). At the same time, scales with a heterogeneous structure were noted (the coefficient of variation exceeds 30 %). This group of scales also includes "Role functioning due to physical condition" and "Role functioning due to emotional condition," a decrease in



levels and heterogeneity of which was noted in SCA1 patients.

The average life quality levels for all types of examined scales and health components in SCA1patients and healthy people were compared to assess the structure of life quality of patients and identify its most sensitive components (Table 4).

Life quality parameters	n	М	σ	U
Physical functioning	12	90.4	13.5	14.9
Role function due to physical condition	12	81.2	35.5	43.7
Pain intensity	12	76.3	23.7	31.0
General health	12	59.9	15.7	26.2
Life activity	12	52.0	26.3	50.5
Social functioning	12	69.7	29.8	42.8
Emotional Role Function	12	75.0	32.1	42.9
Mental health	12	63.3	18.9	29.9
Physical component of health	12	76.9	15.6	20.3
Psychological component of health	12	65.0	24.2	37.3
Average Life Quality Assessment	12	71.0	18.8	26.5

Table 3. 1	ndicators	of life qu	ality of I	healthy
representa	tives of th	e Yakut	populati	on

Note: n - number of observations; M -average value; σ - standard deviation; v - variation coefficient

Table 4. Comparison of average estimates of life quality of SCA1 patients and healthy representatives of the Yakut population

Life quality parameters	U	z	р
Physical functioning	16.0	-3.20	0.000
Role function due to physical condition	28.0	-2.51	0.010
Pain intensity	29.0	-2.45	0.012
General health	36.5	-2.02	0.038
Life activity	72.0	0.02	1.000
Social functioning	54.0	-1.01	0.318
Emotional Role Function	21.5	-2.88	0.002
Mental health	61.5	-0.57	0.551
Physical component of health	19.5	-3.00	0.001
Psychological component of health	44.0	-1.58	0.113
Average Life Quality Assessment	27.0	-2.56	0.008

Note: U - Mann-Whitney test; z - standardized value of the criterion; <math>p - two-way exact level of statistical significance

The research results established that a decrease in the life quality occurred for most indicators in the studied hereditary neurological pathology. This is evidenced by statistically significant differences in their averages compared to healthy individuals. At the same time, it seems interesting that patients maintain a level of life quality that does not differ from that of healthy persons due to the scales "Life activity," "Social functioning," "Mental health" and psychological health in general.

4. CONCLUSION

The pathology significantly reduces the life quality of patients according to the results of the Yakut population. First of all, the emotional state of the patients is deteriorating, which makes them spend more time doing everyday work, as well as reducing its volume. The next most important for patients is the deterioration of physical condition, which also greatly complicates the performance of daily work and household duties. On the other hand, even among healthy individuals, these parameters are characterized by wide variability with fairly high average scores.

The life quality feature of Yakut SCA1 patients can be considered a relatively good preservation of mental health, i.e., an optimistic attitude and positive emotions remain with a fairly low level of depressive and anxious experiences in general. Patients also maintain vital activity, normal level of communication and social contacts that are quite comparable to those of healthy persons. All this has a positive effect on the psychological component of the health of patients with SCA1.

Thus, established positive assessments of psychological health in SCA1 patients can contribute to the successful implementation of preventive measures and genetic screening in affected families. In addition, it is necessary to conduct psychological consultations and training improving the emotional state of patients.

The work was supported by the State Task of the Ministry of Science and Higher Education of the Russian Federation (project No. FSRG-2020-0014 "Genomics of the Arctic: epidemiology, heredity and pathology").

REFERENCES

- A.M. Duenas, R. Goold, P. Giunti, Brain 129 (2006) 1357–1370.
- [2] P. Meera, S.M. Pulst, T.S. Otis, J. Physiol. 594 (2016) 4653–4660.
- [3] D.R. Lynch, J. Farmer, J. Neuroophthalmol. 22 (2002) 297–304.



- [4] G. Coarelli, A. Brice, A. Durr, F1000Res. 7 (2018) 1781.
- [5] S.H. Subramony, T. Ashizawa, in: R.A. Pagon et al. (Eds.), GeneReviews, Univ. of Wash., Seattle, WA, 2015.
- [6] I. Paradisi, V. Ikonomu, S. Arias, J. Hum. Genet. 61 (2016) 215–222.
- [7] F.A. Platonov, K. Tyryshkin, D.G. Tikhonov et al., Neurogenet. 17 (2016) 179–185.
- [8] N. Buttner, D. Geschwind, J.C. Jen et al., Arch. Neurol. 55 (1998) 1353–1357.
- [9] C.D. Stephen, J.D. Schmahmann, Cerebell. 18 (2019) 1130–1136.
- [10] F.A. Klok, K.W. van Kralingen, A.P. van Dijk et al., Chest. 138 (2010) 1432–1440.
- [11] A. Bunevicius, Health Qual. Life Outcomes 15 (2017) 92.